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The HIV-1 Rev protein is an essential nuclear regulatory viral protein. Rev mutants that are able to block wild-type (WT) Rev
activity in trans have been reported and used in antiviral approaches. Not only nuclear but also cytoplasmic Rev mutants were
described and suspected to be transdominant by retaining WT Rev in the cytoplasm. To investigate their potential for cytoplasmic
retention, we studied the localization, trafficking, and interactions of cytoplasmic Rev mutants containing mutations in the
N-terminal multifunctional domain. Using a novel dual-color autofluorescent protein-tagging system, we found that coexpression
of the nucleolar blue-tagged WT Rev protein together with green-labeled cytoplasmic Rev mutants did not result in the retention
of WT Rev in the cytoplasm but, on the contrary, in colocalization of the mutants to the nucleolus. A combination of mutations
abolished the interaction with WT Rev, defining two domains important for Rev protein interaction. The identified domains were
also essential for specific Rev responsive element (RRE) RNA binding and nuclear retention. Inactivation of the nuclear export
signal shifted the steady-state distribution of the mutants from the cytoplasm to the nucleus, indicating their capability for
nucleo-cytoplasmic shuttling. The cytoplasmic mutants were not transdominant compared to the nuclear mutant RevM10BL.
These results emphasize that efficient oligomerization with WT Rev combined with RRE-specific RNA binding are prerequisites for
effective transdominance.
INTRODUCTION
The Rev protein is an essential factor for replication of
the human immunodeficiency virus type 1 (HIV-1) (for de-
tailed reviews, see Cullen, 1991; Parslow, 1993; Felber, 1997;
Pavlakis, 1997). Rev promotes the transport, stability, and
translation of unspliced and partially spliced HIV-1 mRNAs
responsible for the production of the viral structural pro-
teins. The effects of Rev on the posttranscriptional control of
gene expression are mediated by the binding to a unique
RNA stem-loop structure termed Rev responsive element
(RRE) identified in the env coding region of HIV-1. Rev
accumulates in the nucleolus but constantly shuttles be-
tween the nucleus and the cytoplasm. Two regions impor-
tant for function have been defined. The N-terminal region,
approximately residues 14–60, contains the specific RRE
binding domain, an arginine-rich nuclear/nucleolar localiza-
tion signal, and residues important for oligomerization. A
C-terminal leucine-rich effector domain (NES) mediates nu-
clear export (for review, see Hope, 1997). Potential candi-
dates like the eukaryotic initiation factor eIF-5A or CRM1
have been proposed as cellular shuttle factors (Bevec et al.,
1996; Fornerod et al., 1997). Mutations in the Rev effector
domain prevent Rev’s export and cause a dominant nega-
tive phenotype. This appears to be mediated by the forma-
tion of heteromultimers between Rev and transdominant
(TD) Rev, which results in the inhibition of the nucleocyto-
plasmic transport of Rev (Hope et al., 1992; Stauber et al.,
1995; Szilvay et al., 1995). Kubota et al. (1992) proposed that
a Rev mutant lacking the N-terminal Arg-rich domain was
transdominant by retaining WT Rev in the cytoplasm,
thereby suggesting a new mechanism of transdominance.
Visualizing the interaction of Rev mutants with WT Rev in
the same cell is often hampered by the difficulties to raise
mutant-specific antibodies. In addition, fixation and perme-
abilization procedures necessary for indirect immunofluo-
rescence could give rise to artifacts changing protein local-
ization (D’Agostino et al., 1995; Szilvay et al., 1997; Lee et al.,
1998). Thus we used a novel dual-color autofluorescent
protein-labeling system (Stauber et al., 1998) to study the
trafficking and interactions of cytoplasmic mutants in the
most natural environment, the living cell.
RESULTS
Rev14-GFP and Rev38-GFP are localized
in the cytoplasm
To test if cytoplasmic Rev mutants can affect the
localization of WT Rev in living cells, green fluorescent
protein (GFP) was fused to Rev mutants that localize
predominantly in the cytoplasm. pBRev14-GFP en-
codes a Rev mutant in which the amino acids 14–16
have been changed from RTV to EED (D’Agostino et al.,
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1995) fused to the complete GFP protein. This Rev
mutant was chosen because it was reported to be
cytoplasmic, although it still contained the complete
Arg-rich region [resembling a classical nuclear local-
ization signal (NLS)] and still bound to nuclei in an in
vitro assay (D’Agostino et al., 1995). Likewise, the
mutant Rev38-GFP is a hybrid between GFP and a Rev
mutant in which the basic amino acids 38–44 (RRNR-
RRR) were deleted (Fig. 1). This Rev mutant without the
GFP-tag has been reported to be transdominant (Kub-
ota et al., 1992). As shown previously, Rev-GFP local-
ized almost completely to the nucleolus when ex-
pressed in human cells (Stauber et al., 1995) (see also
Fig. 3B). In contrast, confocal laser scan microscopy
(CLSM) of transfected HLtat cells demonstrated that
both Rev-GFP mutants localized predominantly to the
cytoplasm (Figs. 2A and 2B), although in some high-
expressing cells, Rev14-GFP could also be detected at
the nucleolus. Fixation of the cells led to the detection
of Rev14-GFP at the nucleolus in most cells. We sug-
gest that this is the result of the fixation procedure,
demonstrating an advantage of the GFP technology to
avoid artifacts caused by fixation. The localization of
the Rev-GFP mutants was similar in several other cell
lines tested. Cotransfection of a plasmid encoding an
RRE containing RNA did not cause detectable changes
in protein localization. When tested in a Rev-
dependent Gag expression assay, neither the pres-
ence of Rev14-GFP nor Rev38-GFP could stimulate the
expression of Gag, verifying that both mutations re-
sulted in nonfunctional Rev proteins (data not shown).
The Rev mutants are not defective in nuclear import
but in nuclear retention
To interact with its RNA target, Rev has to be present in
the nucleus. To investigate if the Rev mutants are able to
enter the nucleus, we, in addition, inactivated the nuclear
export signal (NES) in the mutants. Since Rev is a shuttling
protein, the cytoplasmic steady-state localization can be
caused by either lack of entry in the nucleus or by rapid
nuclear export. We reasoned that blocking nuclear export
should result in nuclear accumulation of the Rev mutants if
they are capable of nuclear entry. In contrast, blocking
nuclear export should not change their localization if the
proteins always remain in the cytoplasm. The double mu-
FIG. 1. Schematic representation of the plasmids coding for the different Rev-GFP or Rev-BFP fusion proteins. The constructs contain part of the
HIV-1 59 LTR (U3 and part of the R region, up to nt 180) and the polyadenylation signal (poly A) of SV40. The GFP coding region is indicated by a
shaded bar. In the constructs expressing Rev-BFP or Rev14M10BL-BFP, the GFP coding region is replaced by BFP. AFP indicates GFP or BFP.
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tants containing an inactivated nuclear export signal
(M10BL) (see Fig. 1) were detected predominantly in the
nucleus upon transient transfection (Figs. 2C and 2D). In
contrast to Rev14M10BL-GFP, which accumulated at the
nucleoli, Rev38M10BL-GFP was still excluded from the nu-
cleoli. Similar localization of the double mutants without the
GFP tag could be observed by indirect immunofluores-
cence using Rev-specific antibodies. Treatment of cells
expressing Rev14-GFP or Rev38-GFP with leptomycin, an
inhibitor of the Rev nuclear export pathway, resulted also in
nuclear accumulation of the mutants (data not shown).
These results suggest that a Rev mutant lacking the puta-
tive NLS is still able to enter the nucleus. The steady-state
distribution, however, is predominantly cytoplasmic be-
cause the mutants are not efficiently retained in the nucleus
but are readily exported.
WT Rev is not trapped in the cytoplasm by the Rev
mutants but colocalizes the mutants to the nucleolus
The ability of tagging proteins with different-colored
GFP mutants offered the opportunity to examine the
interaction of Rev proteins in the same cell. If the
mutant Rev-GFP proteins were able to retain blue-
tagged WT Rev in the cytoplasm by complex formation,
it should result in colocalization of blue WT Rev-BFP in
the cytoplasm.
Coexpression of blue WT Rev-BFP together with
Rev14-GFP or Rev38-GFP demonstrated that both mu-
tants were still able to interact with WT Rev. However,
the mutants did not trap WT Rev in the cytoplasm but,
on the contrary, were translocated to the nucleolus by
interaction with WT Rev (Figs. 3A and 3C). The pres-
ence of WT Rev-BFP in the same cell was verified by
a UV-laser excited BFP (Figs. 3B, 3D, and 3F), whereas
GFP was detected independently by excitation with an
argon laser. The double mutant Rev14/38, combining
the mutations 14 and 38 (see Fig. 1), did not colocalize
to the nucleolus with WT Rev (Fig. 3E). Thus the
combination of both mutations abolished the interac-
tion with WT Rev. Our result suggested that two dis-
tinct regions of the Rev protein were important for
efficient protein–protein interaction. However, we can
not exclude the possibility that combining the muta-
tions 14 and 38 could also induce drastic conforma-
FIG. 2. Localization of Rev-GFP mutants in living cells. HLtat cells were transfected with 2 mg of the indicated plasmids, and 24 h later analyzed
by confocal laser scan microscopy (CLSM). Rev14-GFP and Rev38-GFP localized in the cytoplasm (A and B). Inactivation of the nuclear export signal
(M10BL) resulted in the predominant nuclear/nucleolar localization of the double mutants (C and D).
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tional changes in the double mutant Rev14/38, thus
blocking the interaction with WT Rev. To control the
possibility that the mutant Rev14/38 could no longer
interact with WT Rev because it was excluded from the
nucleus, we constructed the mutant Rev14/38-M10BL,
again inactivating the nuclear export signal. Following
FIG. 3. Rev14-GFP and Rev38-GFP but not the double mutant Rev14/38-GFP interact with WT Rev-BFP in living cells. HLtat cells were transfected
with 2 mg of the indicated plasmids and analyzed by CLSM after 24 h. Coexpression of the blue-labeled WT Rev protein together with Rev14-GFP and
Rev38-GFP resulted in their colocalization at the nucleolus (A and C). In contrast, Rev14/38-GFP was not colocalized to the nucleolus in the presence
of WT Rev-BFP (E). The GFP-labeled proteins were detected using an argon laser (A, C, and E), whereas a UV-laser excited the WT Rev-BFP hybrid
(B, D, and F).
FIG. 4. Rev14-GFP and Rev38-GFP are impaired in multimerization. HLtat cells were cotransfected with 2 mg of plasmid DNA expressing the
blue-tagged Rev14M10BL together with Rev14-GFP or Rev38-GFP. The tagged proteins were detected as described in Fig. 3. In contrast to the
presence of WT Rev-BFP (Fig. 3), the cytoplasmic localization of the mutants (A and C) remained unchanged in the presence of Rev14M10BL-BFP (B
and D).
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transfection, this protein was detected in the nucleus,
indicating that the mutant Rev14/38 is not a purely
cytoplasmic protein but has the ability to shuttle
(data not shown). The same protein interactions could
be observed upon cotransfection of blue-tagged
RevM10BL together with Rev14-GFP and Rev38-GFP,
demonstrating that inactivation of the NES did not
abolish Rev multimerization. In addition, cotransfec-
tion of the Rev-GFP mutants with untagged WT Rev or
RevM10BL verified that the mutants were localized to
the nucleolus via specific Rev–Rev protein interaction
(data not shown).
Rev14-GFP and Rev38-GFP are impaired
in multimer formation
Since Rev has to oligomerize on the RRE to function,
we investigated whether the lack of the biological
activity of the mutants was caused by impaired oli-
gomerization. Homomultimer formation was studied by
coexpressing blue-tagged Rev14M10BL-BFP, which lo-
calized primarily to the nucleolus (see Fig. 2C), to-
gether with Rev14-GFP. In contrast to coexpression
with WT Rev-BFP (Figs. 3A and 3C) no significant
green fluorescence was detected at the nucleolus
(Fig. 4A). In addition, Rev38-GFP did not interact effi-
ciently with Rev14M10BL-BFP (Fig. 4C). Again, excita-
tion with the UV laser verified the presence of the blue
Rev14M10BL-BFP at the nucleolus (Figs. 4B and 4D).
These findings indicated that the mutants are impaired
in oligomerization compared to WT Rev in live cells.
Rev14-GFP and Rev38-GFP have lost WT Rev RNA
binding specificity
Specific binding to the Rev response RNA element
(RRE) is essential for Rev function. To characterize the
RNA binding properties, the Rev-GFP fusion proteins
were purified after expression in Escherichia coli and
tested in a bandshift assay in the presence of radio-
labeled RRE RNA. Figure 5A illustrates that purified
Rev (lanes 2–4) and Rev-GFP (lanes 5–7) were able to
interact with RRE containing RNA to form specific
complexes. The altered mobility of the complexes was
caused by the higher molecular weight of Rev-GFP
compared to Rev. Rev38-GFP showed no RNA binding
activity (lanes 11–13). In contrast, Rev14-GFP bound
efficiently to the RNA, but the observed complexes
displayed a different mobility (lanes 8--10). We there-
fore tested the mutants for specific binding to the Rev
primary binding site, present within hairpin loop IIa of
the RRE. We found that in contrast to Rev or Rev-GFP,
Rev14-GFP still bound efficiently to the RRED12S mu-
tant, which lacks the primary Rev binding site (Fig. 5B,
lanes 5–7). We reasoned that mutant Rev14-GFP has
lost, at least partially, WT Rev-specific RRE binding
and interacts with RNA nonspecifically.
Rev14-GFP and Rev38-GFP are not transdominant
Cotransfections of the Rev-GFP mutants together
with WT Rev-GFP at a plasmid DNA ratio of 4:1 did not
result in significant suppression of WT Rev activity as
compared to cotransfection with the transdominant
mutant RevM10BL (plasmid DNA ratio 2:1) (Fig. 6).
Quantitation of the GFP signal produced from the
cotransfected GFP expression plasmid pCMV-GFP-
sg25 showed equal transfection efficiencies. The flu-
orescence resulting from the expression of the low
amount of transfected Rev-GFP plasmids was 32-fold
lower than the signal emitted by the coexpressed
unfused GFP and could not affect the results. In addi-
tion, equal expression levels of the different Rev mu-
tants were verified by Western blot analysis. Cotrans-
fection of the untagged Rev mutants together with WT
Rev also did not result in significant inhibition of WT
Rev activity (data not shown). This finding suggests
that the interaction of the Rev mutants with WT Rev off
the RRE can not always be simply extrapolated to Rev
complex formation on the RRE in vivo.
The Rev mutants appear to be impaired in complex
formation with WT Rev on the RRE in vitro
To address the formation of heteromultimers on the
RRE in vitro, we took advantage of the different mobil-
ity of the RNA–protein complexes formed by recombi-
nant Rev and Rev-GFP hybrids. Competition experi-
ments were performed using varying amounts of Rev
and Rev-GFP mutant proteins (Fig. 7). Heteromultimers
containing both Rev and Rev-GFP mutants should mi-
grate differently compared to homomultimers formed
exclusively by Rev or Rev-GFP mutants, respectively.
We observed a weak formation of intermediate-size
complexes by mixing Rev protein with Rev14-GFP (Fig.
7B, marked with arrows). However, the nonspecific
RNA binding activity of the mutant Rev14-GFP did not
allow us to distinguish clearly between mutant–WT
Rev protein interaction or the binding of Rev14-GFP to
RNA regions unoccupied by WT Rev. Only the mutant
Rev38, which displayed no RNA binding activity, al-
lowed us to study exclusively protein–protein interac-
tion. As illustrated in Fig. 7A (lanes 2–5), we could not
detect intermediate complexes of Rev and Rev38-GFP
under our experimental conditions. This suggests that
Rev mutants lacking RRE-specific RNA binding and
proper oligomerization appear not to participate effi-
ciently in complex formation on the RRE and are thus
not transdominant.
DISCUSSION
In our study, we investigated the potential of cytoplas-
mic Rev mutants (see Table 1) to be transdominant by
trapping WT Rev in the cytoplasm as suggested by Ku-
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bota et al. (1992) and Furuta et al. (1995). Our approach,
which was based on the change of the intracellular
localization of the labeled Rev proteins, demonstrated
that the cytoplasmic Rev mutants were unable to retain
WT Rev in the cytoplasm but, on the contrary, were
transported to the nucleolus via interaction with WT Rev.
FIG. 5. (A) RRE RNA binding activity of the Rev-GFP mutants. The Gel retardation assay was performed incubating purified Rev proteins with
32P-labeled RRE RNA. Lane 1, free RNA probe. In lanes 2–4, 5, 10, or 20 pmol of recombinant Rev or Rev-GFP proteins, respectively, were used. Lanes
5–7 contained 3.4, 6.8, or 13.6 pmol of Rev-GFP protein, respectively. Rev14-GFP protein concentrations were 5.3, 10.6, and 21.2 pmol (lanes 8--10).
Rev38-GFP was used at a concentration of 4.7, 9.4, and 18.8 pmol (lanes 11–13). (B) Rev14-GFP is defective in WT Rev RRE binding specificity. The
RNA binding assay was performed in presence of 32P-labeled RRED12S RNA lacking the primary Rev binding site. Recombinant protein concentra-
tions were: Lane 1, 20 pmol of Rev; lane 2, 13.6 pmol of Rev-GFP; lanes 3 and 4, 18.6 and 28 pmol of Rev38-GFP, respectively; lanes 5 and 6, 21.2 and
32 pmol of Rev14-GFP, respectively; lane 7, free RNA probe.
FIG. 6. The mutant Rev-GFP fusion proteins are not transdominant. 239 cells were transfected with 0.1 mg of pBrev-GFP alone or in combination with
different amounts of the indicated mutant Rev-GFP expression plasmids, together with 1 mg of pL3tat, 1 mg of the gag-expression vector pB37R, and 2 mg
of pCMV-GFPsg25. 48 h later the cells were harvested and intracellular Gag production was measured by a p24gag antigen capture assay. Duplicate 293
plates were used and the results were averaged. Similar results were obtained in two independent experiments. Transfection efficiencies were controlled
quantitating GFP as described in Materials and Methods.
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Thus we suggest that the reported inhibitory effect of
Rev38 on viral replication (Furuta et al., 1995) may be
mediated by an unknown mechanism, e.g., competition
for Rev binding cofactors as suggested in a study on the
HTLV-I Rex protein (Katahira et al., 1995). Alternatively,
inhibition of virus replication in stable Rev38-expressing
cell lines may be an effect not related to the properties of
the Rev38 mutant.
Several in vitro and in vivo studies have indicated
that mutations in the N-terminal multifunctional region
of Rev impair multimerization, although other studies
proposed that deletion of the Arg-rich domain does not
affect oligomerization (Malim et al., 1989; Olsen et al.,
1990; Zapp et al., 1991; Madore et al., 1994; Szilvay
et al., 1997; Thomas et al., 1998). Colocalization of
the single, but not of the double, mutants from the
cytoplasm to the nucleolus via protein interaction in
our study suggested that two domains are important
for Rev oligomerization in live cells. Thus the mutants
are able to interact with WT Rev because one domain
is supplied by WT Rev and the other is presented
by the Rev mutants. Efficient homooligomerization, on
the other hand, appears to be impaired because the
mutants are lacking the second interaction domain.
The study of Thomas et al. (1997, 1998) indicated that
the N-terminal part of Rev displays a protein interac-
tion interface composed of two a-helices contacting
via hydrophobic residues. The mutations described
in this report disrupt either the integrity of helix 1
(Rev14) or helix 2 (Rev38) and are in agreement with
this model. Specific oligomerization of the Rev mutants
off the RRE was not only observed with WT Rev but
also with RevM10BL, demonstrating direct protein in-
teraction with a mutant Rev protein lacking the NES.
This finding supports the proposed mechanism for
transdominance caused by the formation of inactive
heteromultimers between Rev and RevM10BL in the
nucleus (Hope et al., 1992; Stauber et al., 1995; Szilvay
et al., 1995).
The development of autofluorescent proteins with dif-
ferent excitation and emission spectra allows for direct
observation of protein interactions in living cells (Stauber
et al., 1998). Since GFP was shown to dimerize at high
protein concentrations and the structure of BFP is similar
to GFP (Palm et al., 1996), it is important to include an
untagged interaction partner as a control (e.g., unlabeled
WT Rev in this report) to assure the specificity of the
protein interaction. In our study, the GFP-tagged double
mutant Rev14/38 no longer interacted with BFP-tagged
WT Rev, underlining that we were examining specifically
Rev–Rev interactions.
Analysis of the RRE–RNA binding specificity revealed
that not only multimerization but also RNA binding was
FIG. 7. In vitro assay to address complex formation of Rev14-GFP
and Rev38-GFP with WT Rev on the RRE. Complexes of recombinant
WT Rev with 32P-labeled RRE RNA were preformed for 15 min and
subsequently different amounts of Rev38-GFP or Rev14-GFP were
added. (A) Lane 1, free RNA probe; lane 2–4, 5, 10, and 20 pmol of
WT Rev were combined with 20, 10, and 5 pmol of Rev38-GFP,
respectively. Lane 5, RNA incubated with 20 pmol of WT Rev. (B)
Lanes 1–3, 5, 10.6. and 21.6 pmol of Rev14-GFP were combined with
20, 10, and 5 pmol of Rev, respectively. Arrows mark the formed
intermediate complexes. Lane 1, free RNA probe. Triangle, Rev-
complexes; arrows, intermediate Rev/Rev14-GFP complexes; circle,
Rev14-GFP complexes.
TABLE 1
Properties of Rev-GFP Mutants
Protein Localization Multimerizationa Shuttling RRE bindingb Transdominance
Rev-GFP Nucleolus 1 1 1 2
RevM10BL-GFP Nucleolus 1 2 1 1
Rev14-GFP Cytoplasm 1 1 2 2
Rev14M10BL-GFP Nucleus/nucleolus (cytoplasm) 1 2 n.d. 2
Rev38-GFP Cytoplasm 1 1 2 2
Rev38M10BL-GFP Nucleus/ (cytoplasm) 1 2 n.d. 2
Rev14/38-GFP Cytoplasm 2 1 n.d. n.d.
Rev14/38M10BL-GFP Nucleus/ (cytoplasm) 2 2 n.d. n.d.
a Heteromultimerization with WT Rev in vivo.
b Rev-specific RRE binding in vitro. n.d., not determined.
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affected in the mutants. Rev14 was still able to bind to
RNA but lost the specificity of WT Rev for the RRE
structure. This indicated that the Arg-rich region is nec-
essary but not sufficient for RRE-specific RNA binding. It
also underlined the importance of addressing not only
RRE RNA but WT Rev-specific RRE RNA binding (i.e., by
using a RRE RNA lacking the primary Rev binding site) to
fully characterize Rev mutants. Our results indicate that
residues around amino acid 14 are important to maintain
a distinct protein conformation, which allows the posi-
tively charged Arg-rich domain to recognize specifically
the RRE structure. This structure is also essential for the
nucleolar localization of Rev, possibly by binding to 5S
RNA, which at least partially mimics the RRE structure
(Lam et al., 1998).
Although the described mutants were still able to
interact with WT Rev off the RRE, additional inactiva-
tion of the NES in the mutants did not result in a
transdominant phenotype as compared to RevM10BL
(Mermer et al., 1990; Stauber et al., 1995). We rea-
soned that to form a biologically active complex on the
RRE, Rev has to oligomerize correctly using both high-
affinity interaction domains. When using our in vitro
assay, we did not find efficient complex formation on
the RRE between the mutants and WT Rev which
supports this assumption. Alternatively, because the
mutants are impaired in RRE-specific RNA binding, the
correct specificity can be prerequisite for active het-
erocomplex formation on the RRE. Thus Rev mutants
that lack the NES but are still able to oligomerize
efficiently with WT Rev and retain RRE-specific RNA
binding activity (e.g., RevM10BL or RevM10) (Benko et
al., 1990; Malim et al., 1992) remain so far the best
candidates for an anti-HIV-1 gene therapy approach
(Nabel et al., 1994).
Several groups have proposed that cytoplasmic Rev
mutants are biologically inactive because they are ex-
cluded from the nucleus (Berger et al., 1991; Hammer-
schmid et al., 1994). By inactivating the NES in the stud-
ied mutants, we could demonstrate their competence for
nuclear entry. Nuclear accumulation after leptomycin
treatment and complex formation of the mutants with the
nonshuttling nucleolar protein RevM10BL also support
this finding. Since Rev38 is lacking the putative NLS of
Rev (Cochrane et al., 1990; Kubota et al., 1989), we are
currently investigating the importance of the Arg-rich
domain for nuclear entry or nuclear retention in the
context of Rev.
In summary, we have used a two-color GFP-tagging
system to detect protein–protein interactions in living
cells. The two-color approach is straightforward, does
not require subsequent modifications, and may there-
fore be applied widely. With this assay, we demon-
strated that the analyzed cytoplasmic Rev mutants
were unable to retain WT Rev in the cytoplasm but
colocalized with WT Rev to the nucleolus. In addition,
our findings suggest that two domains are important
for efficient Rev oligomerization. The integrity of the
defined domains is also essential for nucleolar accu-
mulation and RRE-specific RNA binding, underlining
the fact that the RNA binding and oligomerization
domains of Rev highly overlap. The cytoplasmic local-
ization of the mutants is not caused by their inability to
enter the nucleus but by their impaired nuclear reten-
tion. No or unspecific RNA binding together with im-
paired multimerization explain why the mutants are
biologically inactive and not transdominant.
MATERIALS AND METHODS
Cells and transfections
For microscopic and functional studies the human cell
lines HLtat and 293 were used (Stauber et al., 1995). Cells
were transfected and cytoplasmic extracts were prepared
as described (Stauber et al., 1995). To assay for Rev activity,
the production of HIV-1 Gag protein was quantitated as
described (Stauber et al., 1995). In experiments using 293
cells, Tat protein was provided in trans by cotransfection
with the Tat-expression plasmid pL3tat (Felber et al., 1990).
To control for transfection efficiency, 2 mg of the GFP-
expressing plasmid pCMV-GFPsg25 (Stauber et al., 1998)
was cotransfected. The GFP signal was quantitated in a
Cytofluor II plate reader (Perseptive Biosystems) equipped
with at 485/20 nm excitation and 530/30 nm emission filter
as described (Stauber et al., 1998).
Recombinant plasmids
pBsrev or pBsrevM10BL produces Rev or RevM10BL,
respectively (Stauber et al., 1995). pB37R expresses gag in
a Rev-dependent manner under the HIV-1 59 LTR promoter
(Stauber et al., 1995). pCMV-GFPsg25 and pCMV-BFPsg50
express enhanced versions of the GFP emitting green or
blue light, respectively, under the control of the CMV early
promoter (Stauber et al., 1998). pBrev-GFP was constructed
by replacing the NheI–BstBI DNA fragment of pBsrev-GFP
(Stauber et al., 1995) by the NheI–BstBI DNA fragment from
pCMV-GFPsg25. pBrev14-GFP was generated by replacing
the AflII–HindIII DNA fragment of pBrev-GFP by the corre-
sponding DNA fragment from pBsrev14-16EED (D’Agostino
et al., 1995). In the plasmid pBrev14M10BL, the HindIII–NheI
fragment of pBrev14-GFP was replaced by the correspond-
ing fragment of pBsrevM10BL. pBsrevM10BL encodes a
transdominant Rev in which the nuclear export signal is
inactivated (Stauber et al., 1995). To obtain the mutant
pBrev38-GFP, the amino acids 38–44 were deleted by
single-stranded site-directed mutagenesis as described
(Schwartz et al., 1992). To clone pBrev38M10BL-GFP, the
HindIII–BglII fragment of pBsrevM10BL-GFP was substi-
tuted by the corresponding fragment from pBrev38-GFP,
and the WT GFP was subsequently replaced with the
mutant GFP from pCMV-GFPsg25 by exchanging the
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NheI–BstBI DNA fragment. In the double mutant pBrev14/
38-GFP, the HindIII–NheI DNA fragment in the plasmid
pBrev14-GFP was replaced with the corresponding frag-
ment from pBrev38-GFP. To generate the mutant
pBrev14/38M10BL-GFP, the same strategy was used to
replace the HindIII–NheI DNA-fragment from pBrev14-
GFP with the DNA sequence from pBrev38M10BL-GFP.
The constructs pBrev14M10BLN and pBrev38M10BLN
encode the mutant Rev proteins Rev14M10BL and
Rev38M10BL, respectively, without the GFP tag. To gen-
erate these plasmids, the constructs pBrev38M10BL-
GFP and pBrev14M10BL-GFP were linearized with NcoI,
treated with Klenow enzyme, and religated.
The constructs pBrev-BFP, pBrevM10BL-BFP, and
pBrev14M10BL-BFP were constructed by replacing the
NheI–BstBI DNA fragments from the plasmids pBrev-
GFP, pBsrevM10BL-GFP, and pBrev14M10BL-GFP, re-
spectively, with the corresponding fragment from the
plasmid pCMV-BFPsg50.
For bacterial expression, the genes coding for WT
and mutant Rev-GFP were cloned into the expression
vector pET3a (Novagen), in which expression is under
the control of the bacteriophage T7 phi10 promoter.
pET3a plasmid DNA was digested with NdeI, treated
with Klenow enzyme, and subsequently digested with
BamHI. To generated compatible DNA ends for clon-
ing, the Rev-GFP or mutated Rev-GFP coding se-
quences were amplified by PCR using appropriate
primers. The amplified DNA fragments were digested
with BamHI and ligated into the modified pET3a vector,
resulting in the plasmids pET3aRev-GFP, pET3aRev14-
GFP, and pET3aRev38-GFP. The construct for the ex-
pression of the untagged WT Rev protein has been
described elsewhere (Mermer et al., 1990). Plasmids
were verified by sequence analysis as described pre-
viously (Stauber et al., 1995).
Microscopy of living cells and image analysis
Cells were seeded into coated 50-mm glass-bottom
microwell dishes (MatTek) or Lab-Tek chamber slides
(Nunc), cultured in phenol red free DMEM (10% FCS) and
transfected after 24 h. One day later, the cells were
analyzed by a Zeiss LSM 410 Micro System in the con-
focal mode. For GFP excitation, an argon/krypton laser at
488-nm wavelength was used, whereas a UV laser at
364-nm wavelength was used to excite BFP. Emitted
fluorescence was detected with a 510- to 540-nm band-
pass filter for GFP or with a 420-nm cutoff filter for BFP,
respectively. Normaski images were made using a
543-nm green laser and appropriate polarized lenses.
Indirect immunofluorescence
Transfected cells were fixed, permeabilized, and incu-
bated with a polyclonal rabbit anti-Rev antiserum (diluted
1:100 in PBS) as described earlier (Stauber et al., 1995).
Appropriate secondary rhodamine conjugated anti-IgG
antibodies (diluted 1:200 in PBS) were added for 1 h, and
cells were analyzed by microscopy. Extensive washings
with PBS were performed after each step throughout the
procedure.
Leptomycin treatment
HLtat cells transfected with the indicated plasmid were
treated after 24 h with leptomycin (6 nM) for 30 min and
examined by fluorescence microscopy without fixation.
Bacterial protein expression and purification
The untagged Rev protein was expressed and purified
as described previously (Benko et al., 1990). To produce
WT and mutant Rev-GFP proteins, the pET3a expression
constructs were transformed into the E. coli strain
BL21(DE3), which expresses T7 RNA polymerase under
the control of the lac repressor. Cells were grown to a
OD660nm of 0.6, and subsequently gene expression was
induced by adding IPTG to a final concentration of 0.5
mM. Three hours later the cells were harvested and
lysed by sonication.
Rev-GFP was purified from inclusion bodies after sol-
ubilization in 7 M urea and 20 mM Tris-HCl (pH 8.9),
applied on a Mono Q column, and eluted with 300 mM
NaCl. After repetition of chromatography on a Mono Q
column, Rev-GFP was refolded by rapid dilution into
10-fold excess of 20 mM Tris-HCl (pH 8.9), subjected to
another Mono Q step without urea, and eluted with 350
mM NaCl.
Rev14-GFP and Rev38-GFP were purified by a three-
step procedure. Crude cell extracts containing 20 mM
Tris-HCl (pH 7.5) and 800 mM ammonium sulfate were
applied on a phenyl-Sepharose column. The column was
washed with a reverse gradient of ammonium sulfate
and proteins were eluted with 20 mM Tris-HCl (pH 8.5).
Fractions containing Rev14-GFP or Rev38-GFP were sub-
sequently applied on a Mono Q column as described
above. Fractions from the Mono Q column were dialyzed
against 20 mM Tris-HCl (pH 8.5) and applied on a cellu-
lose phosphate column. Recombinant Rev14-GFP or
Rev38-GFP were eluted with 400 mM NaCl. The purified
Rev-GFP proteins showed one major band on a denatur-
ing polyacrylamid gel with an apparent molecular weight
close to 43 kDa.
RNA binding assay
In vitro transcription and RNA binding assay were per-
formed as described (Benko et al., 1990). The HIV-1 env
gene sequence (nt 7352--7417) encoding the Rev response
element was inserted as an XhoI–HindIII PCR fragment into
pBluescriptKS1 (Stratagene), resulting in the plasmid
pKSR72S. Plasmid DNA was linearized at the HindIII site
and transcribed in vitro to generate RRE RNA (72 nt). Plas-
mids pGEMRRE330 and pGEM RRED12S was used to
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generate RRE330 RNA and D12SRRE (Benko et al., 1990).
The D12SRRE RNA lacked the high-affinity Rev binding site
stem-loop IIa.
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